Related Experiment Video
Updated: Jan 9, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
The Factor Approach: Coagulation Treatment Optimization and Recommendations (FACTOR)
Sara Leidy1, Zahra Mahmoudjafari1
1From The University of Kansas Cancer Center, Westwood, Kansas.
Abstract:
Exogenous blood factor products, such as recombinant or human-derived factor VIIa, factor VIII, factor IX, and von Willebrand factor, are crucial for treating various bleeding disorders, but come with high risks and costs. Effective formulary management and development of institutional evidence-based guidelines for blood factor products are essential to maximize patient outcomes and minimize adverse events through an interprofessional approach. This article details the steps and considerations involved for the development of a blood factor product formulary and management at an academic medical center.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Clot Retraction and Fibrinolysis